P

Pfizer

Makes cancer drugs, vaccines and other medicines

General Manager - Metabolism BU

Full-TimeUpdated on 10/15/2026
No salary listed
Expert
Bachelor's, Master's
Shanghai, China
In Person
Business & Strategy

About the job

Requirements
  • At least 15 years of diverse commercial experience, including management and people-manager experience.
  • Extensive pharmaceutical and broader healthcare business knowledge.
  • A proven track record of successful product launches in primary care and across hospital, e-commerce, and retail channels, or a clear understanding of these channels.
  • Fluent written and spoken English.
  • A bachelor's degree is required; a master's degree is preferred.
  • P&L management experience and financial acumen.
  • Ability to lead high-performing teams while maintaining integrity and inspiring and motivating the organization toward common goals.
  • Demonstrated ability to build alignment behind a unified team goal and lead an organization to success.
  • Strong analytical, strategic-thinking, and problem-solving skills, including identifying opportunities and making data-driven decisions.
  • Performance-driven approach and a high level of accountability for consistently achieving goals.
  • Excellent communication skills and ability to articulate winning strategies for hospital and consumer business.
  • Agility, resilience, and adaptability.
  • Ability to anticipate changes in the healthcare environment and use an innovative mindset to embrace change and identify innovative solutions.
  • Ability to engage, influence, and convince global therapeutic-area colleagues and other key stakeholders.
  • Ability to lead conversations with key stakeholders to strengthen the therapeutic area's position.
  • Ability to work in a matrix organization.
  • Ability to motivate and develop talent.
  • Good understanding of market access and pipeline development for metabolism products.
  • Commitment to the One Pfizer and Bold Move organization imperatives.
Responsibilities
  • Set a long-term vision and develop category-specific strategies to maximize patient impact and Pfizer revenue.
  • Develop and implement strategies to increase product awareness, market penetration, and revenue generation across the region.
  • Ensure launch readiness for new products and indications through robust launch strategy development and market preparedness.
  • Establish innovative go-to-market approaches to address barriers to meeting unmet patient needs in China and continually improve disease awareness, accessibility, and affordability in the therapeutic area.
  • Drive execution of campaigns, plans of action, tactics, customer plans, and successful launches of key brands within the category.
  • Optimize business performance and manage daily operations.
  • Manage and integrate sales efforts across hospital, e-commerce, and retail channels, driving cross-channel synergies and aligning strategies and performance metrics to maximize growth.
  • Optimize category revenue growth and manage IBT through trade-off and resource-allocation decisions that enable growth through focused investments.
  • Manage expenses and investments according to plan goals.
  • Monitor business performance and implement corrective actions in agreement with the China President and leadership team.
  • Drive strategic portfolio planning and collaborate with internal stakeholders to accelerate the pipeline and explore innovative pathways.
  • Build alignment across functions and management layers to advocate for China priorities in metabolism and secure sufficient pipeline investment to optimize future growth potential.
  • Proactively engage and influence internal stakeholders to advocate for China metabolism business priorities, align cross-functional support with business needs, and obtain leadership buy-in.
  • Lead scientific conversations with external stakeholders, including key opinion leaders and government, and strengthen Pfizer China's engagement and influence in the metabolism ecosystem to improve the lives of patients in China.
  • Lead and coach a high-performing team, develop colleagues in line with Pfizer competency models, and inspire colleagues to commit to business objectives and create a climate and values that support short- and long-term success.
  • Ensure activities comply with company policies, standard operating procedures, Pfizer values, and applicable global guidelines, including MAPP and FCPA.
  • Serve as a key member of the Pfizer China leadership team and contribute to Pfizer China's overall success.
  • Represent Pfizer and engage with government officials, industry associations, key opinion leaders, customers, and media to communicate Pfizer's values and mission.
  • Build the ecosystem for metabolism patients and contribute to advancing the company's leadership in the metabolism field.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.

Yahoo Finance
Oct 12th, 2026
UPS, Pfizer, Kraft Heinz and Ford dividends at risk as payouts outstrip earnings

Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.

Business Wire
Oct 7th, 2026
Pfizer's TUKYSA wins FDA approval for front-line HER2+ metastatic breast cancer maintenance treatment

The FDA has approved Pfizer's TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for front-line maintenance treatment of adults with HER2-positive metastatic breast cancer. This chemotherapy-free option expands TUKYSA's use to an earlier disease stage. The approval follows Phase 3 HER2CLIMB-05 trial results showing median progression-free survival of 24.9 months versus 16.3 months with placebo—8.6 additional months without disease progression. The treatment reduced risk of progression or death by 35.9%. Most common adverse events included diarrhoea, musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash, and vomiting. One fatal case of drug-induced liver injury occurred. TUKYSA was previously approved for second-line HER2-positive metastatic breast cancer treatment in 2020. HER2 is overexpressed in 15-20% of breast cancers.

Yahoo Finance
Oct 7th, 2026
Buffett indicator hits 235.8% as Oracle warns investors 'playing with fire' — 3 undervalued stocks to buy

Warren Buffett's favourite valuation metric, the ratio of total market capitalisation to GDP, has reached 235.8%, well above the 200% level he warned constitutes "playing with fire". The indicator sits near its record high from September 2026. Despite elevated overall market valuations, three stocks remain attractively priced. Enterprise Products Partners trades at 11.9 times forward earnings whilst offering a 6% distribution yield, benefiting from increased natural gas demand from AI data centres. JPMorgan Chase trades at 13.5 times forward earnings and could benefit from rising interest rates. Pfizer trades at just 9.7 times forward earnings with a 6.3% dividend yield, though it faces patent cliff challenges through 2028.